MariMed Inc. (OTCMKTS:MRMD – Get Free Report) was the target of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 1,000 shares, a decrease of 97.8% from the September 15th total of 44,669 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 1,661,239 shares, the short-interest ratio is presently 0.0 days.
MariMed Price Performance
Shares of OTCMKTS:MRMD traded down $0.00 during trading on Friday, reaching $0.06. 192,523 shares of the company’s stock traded hands, compared to its average volume of 715,688. The company has a quick ratio of 0.34, a current ratio of 0.92 and a debt-to-equity ratio of 1.78. MariMed has a fifty-two week low of $0.06 and a fifty-two week high of $0.18. The company has a 50-day simple moving average of $0.07 and a 200-day simple moving average of $0.07. The firm has a market cap of $25.55 million, a PE ratio of -1.58 and a beta of 1.39.
MariMed (OTCMKTS:MRMD – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $41.92 million during the quarter, compared to analysts’ expectations of $39.80 million. MariMed had a negative return on equity of 10.71% and a negative net margin of 9.13%.
About MariMed
MariMed, Inc is a U.S.-based cannabis company that develops, operates, and manages state-licensed cannabis businesses. Its activities include cannabis cultivation, product manufacturing, wholesale distribution, and retail dispensary operations.
The company offers cannabis products such as flower, pre-rolls, concentrates, edibles, tinctures, and topical products. Its portfolio has included brands such as Betty’s Eddies, Nature’s Heritage, InHouse, and Kalm Fusion, which are distributed through MariMed-operated dispensaries and other licensed retail channels.
MariMed serves regulated cannabis markets in multiple states, including Massachusetts, Maryland, Delaware, and Ohio.
See Also
- Five stocks we like better than MariMed
- 3 Unique ETFs With Strong Momentum for the End of the Year
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
- Schneider Just Paid Up for PTC—Is the SaaSpocalypse Overdone?
- Delta Air Lines Faces a Fuel Crisis—But There’s a Silver Lining
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
